Almost all websites have a Home link at the top to navigate back to the home or front page. The previous Seeking Alpha site also had it.
Please bring it back.
You can go back to the home page by clicking on the Home Icon on the top left corner of the screen.
If you continue to experience difficulties please send us an email to: firstname.lastname@example.org
If i open 5 articles from premium authors, chat window is opened on all them and sound is annoying (make the sound mute by default) or removing chat which is a better solution. If anyone wants to chat, one can open a separate window for chatting.
If you mute the chat in the upper right corner it will remember your setting on all future windows/tabs you open. If you are subscribed to multiple services, the mute doesn't carry over from service to service - you have to adjust volume once per service as users may want to get a ping on one service and not another at a given time.
You can also minimize the chat window next to the sound button - though this is required in each window/tab you have open. Many users have indicated that they prefer to have chat open in all their windows by default so 'they don't miss anything'.
Hope this helps.
Is there any way SA can speed up the load time for its charts...both the standard chart and especially the advanced one. One thing investors truly hate is to WAIT!
Thanks for your feedback.
For the advanced chart, we are working with our partner, TradingView to improve the load time for the chart. We will update this thread once we release those improvements.
For the standard chart, we haven't heard complaints from other users but we encourage others to comment on this thread if they indeed encounter similar issues.
SA Product Manager
I was many year free subscriber, after all went to premium and what! Can't post all moderating!!! Well Thanks SA I remove premium no anymore enjoy
I am currently receiving too many earnings call transcript email notifications. How can I edit my preference to stop receiving these?
Regarded Solutions' June 18th column NOT free despite the author's ongoing promise that all his contributions would be free. Please explain.
CEO LETTER COVID-19 CLINICAL TRIAL
These are unprecedented and challenging times. My priority has been the safety and health of our employees and their families, and to continue the Company’s clinical trials as far as is feasibly possible.
At the same time, we have been working hard to see how we might help in the fight against COVID-19 more directly. On 28 April we announced our participation in a new UK national multi-centre randomised Phase 2 clinical trial initiative called ACCORD (ACcelerating COVID-19 Research & Development platform). BerGenBio’s bemcentinib was selected as the first candidate to be tested for its efficacy and safety in patients hospitalised with COVID-19.
Whilst our clinical focus for bemcentinib, a highly selective and potent inhibitor of AXL kinase, has been on the treatment of cancer, we have been aware of bemcentinib’santi-viral potential for some time, as demonstrated in preclinical models against viruses such as Ebola and Zika, with recent data expanding this to SARS-CoV-2. Bemcentinibselectively inhibits AXL kinase activity, blocking viral entry and enhancing the anti-viral type I interferon response, a key cellular defence mechanism against viral infection.
We are aware of the privilege and importance of having our drug selected for this national study and will be working closely with the Government Scientific Office, the National Institute for Health Research and designated CRO IQVIA to produce timely and high-quality results. If positive results are seen, bemcentinib will advance rapidly to Phase 3 testing and prepare for commercialisation to treat COVID-19 patients.
I’m particularly grateful and impressed by the vital pre-clinical research carried out by Professor Wendy Maury and her team at the University of Iowa, which discovered that the essential role of AXL is hi-jacked by viruses such as EBOLA and SARS-CoV-2 to enhance their infection rate and substantially improve their survival in host cells, and furthermore demonstrated the potential of bemcentinib as a treatment for viruses such as COVID-19. I also thank, and recognise the incredible effort made by, the BerGenBio team, alongside Tom Wilkinson’s team at the University of Southampton and IQVIA, to enable this important trial to get started so rapidly.
As for any company in the healthcare industry, we are seeking to improve the lives and treatment options for patients across the globe. This study will be important not only for COVID-19 patients, but should also serve to further validate bemcentinib as a promising treatment candidate for other aggressive diseases.
We look forward to keeping you all updated as we progress with the study, with the hope that bemcentinib can contribute to the global efforts to find an effective treatment for COVID-19.
Customer support service by UserEcho